Indicated for the treatment of symptoms of seasonal or perennial allergic rhinitis in adults, adolescents and children between 6-11 years of age.
Indicated for the prophylactic treatment of seasonal allergic rhinitis in adults and adolescents 12 years of age and older.
It can be administered in children between 2 and 6 yearsof age with the diagnosis of allergic rhinitis. Prophylactic treatment should be initiated two to four weeks prior to the anticipated start of the pollen season.
Also indicated for the treatment of nasal polyps (its relevant symptoms including congestion and loss of the sense of smell) in adults 18 years of age and older.
|Active Ingredient:||Mometasone furoate|
|Dose of Active Ingredient:||500 mcg/1 g suspension|
|Packing Form/Size:||In metered dose packages containing suspension of 18 g for 140 pulverisations|
|Direction of Use||Summary of Product Characteristics|